Nomura Holdings’s BridgeBio Pharma BBIO Stock Holding History

Nomura Holdings’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,000	Closed	-$1.56M	–	1800
2026 Q1	$1.56M	Sell	21,000 -100,000	-83%	-$7.25M	﹤0.01%	1004
2025 Q4	$9.26M	Buy	121,000 +95,500	+375%	+$6.27M	0.01%	547
2025 Q3	$1.32M	Sell	25,500 -71,300	-74%	-$3.48M	﹤0.01%	1301
2025 Q2	$4.18M	Buy	96,800 +12,800	+15%	+$466K	0.01%	618
2025 Q1	$2.9M	Buy	84,000 +57,500	+217%	+$1.94M	0.01%	912
2024 Q4	$727K	Buy	26,500 +18,000	+212%	+$465K	﹤0.01%	1632
2024 Q3	$216K	Buy	+8,500	New	+$223K	﹤0.01%	1387
2023 Q3	–	Sell	-40,000	Closed	-$688K	–	1379
2023 Q2	$688K	Hold	40,000	–	–	﹤0.01%	995
2023 Q1	$663K	Buy	+40,000	New	+$466K	﹤0.01%	1097

Other funds holding BBIO

Jupiter Topco New York $245B AUM

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Nomura Holdings's BBIO Position: Q2 2026 in Review

Nomura Holdings increased its BridgeBio Pharma (BBIO) stake by 2.8% in Q2 2026, buying an estimated $624K and bringing the position to 327,475 shares worth $24.4M. The position accounts for 0.03% of the portfolio, ranked #317.

Nomura Holdings first reported a position in BBIO in Q3 2020 and has held it in 24 quarters since. 476 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Nomura Holdings held 327,475 shares of BridgeBio Pharma worth $24.4M as of Q2 2026.
Nomura Holdings bought 8,912 BridgeBio Pharma shares in Q2 2026, an estimated $624K.
BridgeBio Pharma made up 0.03% of Nomura Holdings's portfolio in Q2 2026, its #317 holding.
Nomura Holdings first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 24 quarters since.
476 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.